Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Oncotarget|July 16, 2014
Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancerYilin Li, Xiaotian Zhang, Sai Ge, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|May 3, 2014
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma]Xiaotian Zhang, Yuanhang Wu, Jifang Gong, et al.
Cancer Medicine|January 28, 2016
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapyFurong Kou, Zhihao Lu, Jian Li, et al.
Cancer Science|January 23, 2016
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trialMing Lu, Xicheng Wang, Lin Shen, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2026
A two-step scoring model incorporating visceral-to-subcutaneous fat ratio and systemic immunoinflammatory index for predicting cytokine release syndrome severity in patients with gastric cancer receiving Claudin18.2-targeted CAR-T cell therapyMeng He, Lian Liu, Zifan Chen, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 20, 2020
Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive SystemZhi Ji, Yong Cui, Zhi Peng, et al.
Journal of Hematology & Oncology|July 1, 2026
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancerChang Liu, Hongxi Zeng, Jiarui Li, et al.
BMC Cancer|February 10, 2016
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trialJifang Gong, Tianshu Liu, Qingxia Fan, et al.
Plos One|March 4, 2014
Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance?Zhihao Lu, Li Yang, Jingwei Yu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2017
HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancerHaixing Wang, Beifang Li, Zhentao Liu, et al.
Pageof 10